Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces that it has raised €5 million in gross proceeds through a private placement (the “Transaction”) of new shares (the “New Shares”) completed prior to the open of the market today.
The Company has placed 746,269 New Shares with a small group of existing and new institutional investors at a price of €6.70 per New Share, which represents a 11% discount to the closing price of June 12, 2017. The New Shares represent 5.3% of the current number of outstanding shares (pre-Transaction) and will bring the total number of shares (post-Transaction) to 14,712,770. In addition, the investors have received 746,269 5-year warrants entitling them to subscribe for 746,269 new Company shares at a warrant exercise price of €7.70 (the exercise price being subject to adjustment in case of certain corporate and dilutive events).
The New Shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels following their issuance, which is expected to take place on June 15, 2017.
Kiadis Pharma will use the net proceeds of the Transaction to advance the clinical development of the Company’s ATIR products and for general corporate purposes.
Arthur Lahr, Chief Executive Officer of Kiadis Pharma, commented: “Having recently filed a Marketing Authorization Application for ATIR101™ with EMA, the Company continues to make good progress regarding the Phase III trial and preparing for EU commercialization. We executed this private fundraising to quickly augment our cash position while we work on broader funding initiatives. In this Transaction, we are pleased to see existing shareholders increasing their holdings, and welcome new specialist healthcare investors.”
Chardan acted as Sole Bookrunner and Placement Agent for the Transaction. Saola Healthcare Partners acted as financial advisor to Kiadis Pharma.
About Kiadis Pharma
Kiadis Pharma is focused on cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company’s product candidates, ATIR101™ for blood cancers and ATIR201™ for inherited blood disorders, have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective.
Based on the significant and positive results from the single dose Phase II trial with lead product ATIR101™ in patients with blood cancer, which were presented on December 5, 2016 at the Annual Meeting of the American Society of Hematology (ASH), the Company has initiated a Phase III trial with ATIR101™, having received regulatory approval in various countries to start dosing patients. In addition, and based on the positive Phase II results, the Company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ATIR101™ across Europe as an adjunctive treatment in HSCT for malignant disease. ATIR101™ has been granted Orphan Drug Designations both in the US and Europe.
The Company’s second product candidate, ATIR201™, addresses inherited blood disorders with an initial focus on thalassemia. ATIR201™ Phase I/II clinical development has been initiated recently with regulatory approvals having been received in various European countries to start the trial.
Kiadis Pharma was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the EMA. The Company’s shares are listed on Euronext Amsterdam and Euronext Brussels. For more information visit www.kiadis.com
For more information, please contact:
Arthur Lahr, CEO Kiadis Pharma
Tel. +31 20 314 02 50
International Media and Investor Contact:
Mary-Jane Elliott, Lindsey Neville, Hendrik Thys
Consilium Strategic Communications
Tel: +44 (0) 203 709 5708